Fulgent Genetics price target lowered to $20 from $27 at UBS

UBS analyst Dan Leonard lowered the firm’s price target on Fulgent Genetics (FLGT) to $20 from $27 and keeps a Neutral rating on the shares. The company reported a slight Q4 beat but guided 2025 lower, the analyst tells investors in a research note. The firm expects Fulgent’s growth to decelerate going forward given lower growth trends in its commodity oncology and pathology business.